Viridian Therapeutics Inc. (VRDN)
Summary
Viridian Therapeutics: Two Products, One Commercial Buildout
Viridian Therapeutics shifts focus from regulatory risk to launch execution after FDA approval of Lumvoa for thyroid eye disease (TED). VRDN aims to leverage its commercial infrastructure for both Lumvoa and investigational elegrobart, potentially improving franchise economics and operational efficiency. The current valuation is demanding, with no near-term asset-based floor; future profitability hinges on successful commercialization and infrastructure sharing.
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know
Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.
Viridian Therapeutics: Lumvoa Ready For Prime Time Following FDA Approval
Viridian Therapeutics received early FDA approval for Lumvoa, offering a label advantage over Amgen's Tepezza in thyroid eye disease. Lumvoa's shorter infusion course, inclusion of chronic TED data, and immediate availability position VRDN for commercial success, though management is tempering near-term revenue expectations. Elegrobart's underwhelming REVEAL-1 phase 3 results limit its competitive edge in active TED but highlight its convenience and potential in underpenetrated chronic TED based on REVEAL-2 study results.
Viridian Therapeutics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 266 | $4,669.7 | $4,889.08 | $219.38 | 4.7% |
| BG Bart Gancher Intech Investment Management LLC | 28,413 | $450,233.8 | $555,758.28 | $105,524.48 | 23.44% |
| MBV Matthew B. Vawter NATIONS FINANCIAL GROUP Inc., /IA/ /ADV | 11,272 | $207,067 | $214,506.16 | $7,439.16 | 3.59% |
| KT Kevin Tang Tang Capital Management LLC | 1.79M | $33.33M | $32.95M | -$382,098.38 | -1.15% |
 John H. Burbank III Passport Capital LLC | 2.38M | $39.02M | $46.68M | $7.67M | 19.65% |
Viridian Therapeutics Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| GR Gregory Renza Truist Securities | 254.82 | $3,638.78 | $4,906.5 | $1,267.72 | 34.84% |
Viridian Therapeutics Inc. (VRDN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Viridian Therapeutics Inc. ever had a stock split?
Viridian Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stephen F. Mahoney CEO | NASDAQ (CM) Exchange | 92790C104 CUSIP |
| US Country | 252 Employees | 13 Nov 2020 Last Dividend | 13 Nov 2020 Last Split | 18 Jun 2014 IPO Date |
Overview
Viridian Therapeutics, Inc. is a pioneering biotechnology company focused on the research and development of innovative treatments for serious and rare diseases. Originating in 2010 and based in Waltham, Massachusetts, the company underwent a significant rebranding from its former identity as Miragen Therapeutics, Inc., embracing the new name Viridian Therapeutics, Inc. in January 2021. This strategic move marks its commitment to advancing healthcare solutions and addressing unmet medical needs through its extensive research in monoclonal antibody technologies and other therapeutic approaches.
Products and Services
- VRDN-001:
- VRDN-003:
- VRDN-006:
- VRDN-008:
A cutting-edge monoclonal antibody specifically targeting the insulin-like growth factor-1 receptor (IGF-1R), VRDN-001 is currently in Phase 3 clinical trials for patients with thyroid eye disease (TED). This promising treatment exemplifies the company's focus on delivering breakthrough solutions for debilitating conditions.
As part of Viridian Therapeutic's commitment to innovating within its field, VRDN-003 represents the next generation of IGF-1R humanized monoclonal antibodies. It incorporates advanced half-life extension technology, offering potential for enhanced treatment of TED. By focusing on the specificity and longevity of antibody interaction, VRDN-003 aims to improve patient outcomes significantly.
This preclinical program underscores the company's dedication to extending its reach beyond TED, exploring the potential of its technology in treating autoimmune diseases. VRDN-006 is at the forefront, representing a bold step into uncharted territories of immunology and therapeutic intervention.
Another promising venture into the realm of autoimmune disease treatment, VRDN-008 shares the stage with VRDN-006 in preclinical development. Together, they signify Viridian Therapeutics' broader ambitions to diversify and enrich their portfolio, addressing a range of autoimmune disorders with innovative, targeted solutions.
Contact Information
